A Pharmacokinetic (PK) Study of a Combination of Indinavir, Ritonavir, and Amprenavir
HIV Infections
About this trial
This is an interventional treatment trial for HIV Infections focused on measuring Antiretroviral drugs, Pharmacokinetic, Indinavir, Ritonavir, Fosamprenavir
Eligibility Criteria
Inclusion Criteria: Age 18 years or more Diagnosis of HIV infection or AIDS as previously established by HIV ELISA test and confirmed by Western blot analysis Must have been taking and tolerating IDV/RTV 800/100 mg bid as part of an antiretroviral regimen. Exclusion Criteria: Hepatic abnormality: alanine-aminotransferase (ALT), aspartate- aminotransferase (AST) or total bilirubin (TBR) greater than 3x upper limit of normal Renal insufficiency: serum creatinine greater than 2 mg/dl Co-infection with hepatitis B and/or C viruses Pregnant or breastfeeding Use of concurrent medications known to affect IDV or APV concentrations significantly (e.g. rifampin, rifabutin, non-nucleoside reverse transcriptase inhibitor [NNRTI], other PIs, St John's Wort, herbal preparations)
Sites / Locations
- Grady Infectious Diseases Program